Min Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Min Li has a total of 137 co-authors. Here are the top co-authors by number of shared publications:
- Jidong Jia
Liver Research Center, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China
8 shared publications - Yuanyuan Kong
Clinical Epidemiology and EBM Unit, Beijing Clinical Research Institute, National Clinical Research Center for Digestive Diseases, State Key Lab of Digestive Health, Beijing Friendship Hospital, Capital Medical University, Beijing, China
6 shared publications Tingting Lv
Liver Center, Beijing Friendship Hospital Capital Medical University Beijing China
4 shared publications- Xinyan Zhao
Liver Research Center, Beijing Friendship Hospital, Capital Medical University, Beijing, China
4 shared publications Hong Ma
State Key Laboratory of Digestive Health Beijing China
3 shared publicationsHong You
Liver Research Center, Beijing Friendship Hospital Capital Medical University; National Clinical Research Center for Digestive Diseases Beijing China
3 shared publications
Latest Publications
- Open Access
- 26 October 2026
- Published by Wiley in Health Science Reports
- Vol. 9 (11) , e73438
Association Between Sugar‐Sweetened Beverage Consumption and All‐Cause Mortality in Individuals With and Without Metabolic Syndrome: A Prospective Cohort Study
Background and Aims: To examine the association between sugar‐sweetened beverage (SSB) intake and all‐cause mortality among U.S. adults with and without metabolic syndrome (MetS), and to identify potential nonlinear dose‐response relationships and high‐risk subpopulations. Methods: We analyzed data from 26,885 U.S. adults aged 20–79 years who participated in NHANES 2003–2018. MetS was defined based on the NCEP ATP III criteria. SSB intake was assessed using a single 24‐h dietary recall and quantified as total beverage weight (g/day), energy intake (kcal/day), and sugar intake (g/day). Cox proportional hazards models and restricted cubic splines were used to assess the association of SSB intake and mortality in MetS and non‐MetS groups. Results: Among 8,656 participants with MetS and 18,229 without, total weight and energy intake from SSBs showed non‐linear association with the risk of all‐cause mortality in the MetS participants ( P non‐linear < 0.05), with inflection points of approximately 950 g/day and 90 kcal/day, respectively. Above this level, each standard deviation (SD) increment was associated with 14% (HR: 1.14, 95% CI: 1.01–1.29) and 18% (HR: 1.18, 95% CI: 1.08–1.30) higher mortality risk. For SSB‐derived sugar, the non‐linear trend missed statistical significance ( p = 0.07), though risk nadir appeared at ~20 g/day, with subsequent SD increments linked to a 19% risk increase (HR: 1.19, 95% CI: 1.09–1.30). No linear or non‐linear association was presented among individuals without MetS. Conclusion: High SSB intake is associated with increased all‐cause mortality in adults with MetS, with nonlinear threshold effects.
- 26 October 2026
- Published by Wiley in Health Science Reports
- Vol. 9 (11) , e73438
Open AccessAssociation Between Sugar‐Sweetened Beverage Consumption and All‐Cause Mortality in Individuals With and Without Metabolic Syndrome: A Prospective Cohort Study
Background and Aims: To examine the association between sugar‐sweetened beverage (SSB) intake and all‐cause mortality among U.S. adults with and without metabolic syndrome (MetS), and to identify potential nonlinear dose‐response relationships and high‐risk subpopulations. Methods: We analyzed data from 26,885 U.S. adults aged 20–79 years who participated in NHANES 2003–2018. MetS was defined based on the NCEP ATP III criteria. SSB intake was assessed using a single 24‐h dietary recall and quantified as total beverage weight (g/day), energy intake (kcal/day), and sugar intake (g/day). Cox proportional hazards models and restricted cubic splines were used to assess the association of SSB intake and mortality in MetS and non‐MetS groups. Results: Among 8,656 participants with MetS and 18,229 without, total weight and energy intake from SSBs showed non‐linear association with the risk of all‐cause mortality in the MetS participants ( P non‐linear < 0.05), with inflection points of approximately 950 g/day and 90 kcal/day, respectively. Above this level, each standard deviation (SD) increment was associated with 14% (HR: 1.14, 95% CI: 1.01–1.29) and 18% (HR: 1.18, 95% CI: 1.08–1.30) higher mortality risk. For SSB‐derived sugar, the non‐linear trend missed statistical significance ( p = 0.07), though risk nadir appeared at ~20 g/day, with subsequent SD increments linked to a 19% risk increase (HR: 1.19, 95% CI: 1.09–1.30). No linear or non‐linear association was presented among individuals without MetS. Conclusion: High SSB intake is associated with increased all‐cause mortality in adults with MetS, with nonlinear threshold effects.
- Open Access
- 1 June 2026
- Published by Taylor & Francis in Clinical Ophthalmology
- Vol. ume 20, 1-12
92-Plex Inflammatory Proteomic Signatures in Aqueous Humor of High Myopia and Candidate Biomarkers
Objective: In this exploratory study with a limited sample size, we aimed to investigate inflammation-related proteins in the aqueous humor of high myopia (HM) patients, analyze their correlations with ocular parameters, and screen for potential biomarkers. Methods: 20 age-related cataract patients undergoing surgery (Jan 1, 2025 – Feb 1, 2026) were enrolled: HM group (n=12) and non-HM control (n=8). Aqueous humor was collected preoperatively; 92 inflammation-related proteins were quantified using Olink Target 96 Inflammation Panel. Differential expression analysis, Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis, protein-protein interaction (PPI) network analysis, and Spearman correlation analysis were performed to explore the biological functions of differentially expressed proteins and their relationships with ocular parameters. Results: Nine differentially expressed proteins (DEPs) (FDR q< 0.05, |log2FC|> 0.585) were upregulated in HM vs control, most prominently HGF, CST5, CCL19. Enrichment analyses revealed that the DEPs were mainly enriched in the cytokine-cytokine receptor interaction pathway, chemokine signaling pathway, and immune-inflammatory response-related terms. PPI network analysis identified TWEAK, CXCL5, and CCL19 as core proteins. Exploratory correlation analysis identified several associations of nominal significance (uncorrected p < 0.05) between cytokines and ocular parameters in both HM and non-HM groups (eg, DNER and TWEAK with central corneal thickness, CXCL5 with macular center thickness; HGF with keratometry, spherical equivalent, and axial length; CST5 with macular thickness; TWEAK with choroidal thickness). However, none remained significant after FDR correction for multiple comparisons (all q > 0.25). These findings are considered hypothesis-generating. Conclusion: The upregulation of HGF, CST5, CCL19, TWEAK, CXCL5, and DNER in the aqueous humor of patients with high myopia and their specific correlations with ocular parameters suggest a new molecular perspective for understanding the pathogenesis of high myopia. These preliminary findings suggest that the candidate biomarkers may have potential relevance to high myopia progression; however, independent validation in larger cohorts is needed.
- 1 June 2026
- Published by Taylor & Francis in Clinical Ophthalmology
- Vol. ume 20, 1-12
Open Access92-Plex Inflammatory Proteomic Signatures in Aqueous Humor of High Myopia and Candidate Biomarkers
Objective: In this exploratory study with a limited sample size, we aimed to investigate inflammation-related proteins in the aqueous humor of high myopia (HM) patients, analyze their correlations with ocular parameters, and screen for potential biomarkers. Methods: 20 age-related cataract patients undergoing surgery (Jan 1, 2025 – Feb 1, 2026) were enrolled: HM group (n=12) and non-HM control (n=8). Aqueous humor was collected preoperatively; 92 inflammation-related proteins were quantified using Olink Target 96 Inflammation Panel. Differential expression analysis, Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis, protein-protein interaction (PPI) network analysis, and Spearman correlation analysis were performed to explore the biological functions of differentially expressed proteins and their relationships with ocular parameters. Results: Nine differentially expressed proteins (DEPs) (FDR q< 0.05, |log2FC|> 0.585) were upregulated in HM vs control, most prominently HGF, CST5, CCL19. Enrichment analyses revealed that the DEPs were mainly enriched in the cytokine-cytokine receptor interaction pathway, chemokine signaling pathway, and immune-inflammatory response-related terms. PPI network analysis identified TWEAK, CXCL5, and CCL19 as core proteins. Exploratory correlation analysis identified several associations of nominal significance (uncorrected p < 0.05) between cytokines and ocular parameters in both HM and non-HM groups (eg, DNER and TWEAK with central corneal thickness, CXCL5 with macular center thickness; HGF with keratometry, spherical equivalent, and axial length; CST5 with macular thickness; TWEAK with choroidal thickness). However, none remained significant after FDR correction for multiple comparisons (all q > 0.25). These findings are considered hypothesis-generating. Conclusion: The upregulation of HGF, CST5, CCL19, TWEAK, CXCL5, and DNER in the aqueous humor of patients with high myopia and their specific correlations with ocular parameters suggest a new molecular perspective for understanding the pathogenesis of high myopia. These preliminary findings suggest that the candidate biomarkers may have potential relevance to high myopia progression; however, independent validation in larger cohorts is needed.
- Open Access
- 4 May 2026
- Published by Wiley in Portal Hypertension & Cirrhosis
- Vol. 5 (2) , 129-139
Comparable Diagnostic Accuracy but Discordant Thresholds Between FibroTouch and FibroScan: A Biopsy‐Based Comparative Study
Aims: Accurate noninvasive fibrosis staging is essential in chronic liver disease (CLD). Although both FibroTouch and FibroScan are widely used, differences in technical design may affect measurement consistency. Whether their diagnostic thresholds for liver fibrosis are interchangeable remains unclear. The study aims to compare their diagnostic performance and threshold agreement in a biopsy‐confirmed CLD cohort. Methods: This single‐center, cross‐sectional study included 339 patients with biopsy‐confirmed CLD from February 2014 to March 2019, all of whom underwent biochemical testing, FibroTouch, and FibroScan. Diagnostic performance was evaluated using the area under the receiver operating characteristic curves (AUROCs). Univariable and multivariable linear models were used to identify factors associated with inter‐device liver stiffness measurement (LSM) differences. Misclassification was calculated using manufacturer‐recommended thresholds. Subgroup analysis was conducted among patients with metabolic dysfunction–associated fatty liver disease (MAFLD). Results: Both devices showed excellent diagnostic performance for detecting fibrosis ≥ F2, ≥ F3, and F4, with AUROCs exceeding 0.900, outperforming the fibrosis‐4 index (FIB‐4) and aspartate aminotransferase‐to‐platelet ratio index (APRI) in the entire cohort (FIB‐4 AUROCs: 0.775, 0.801, and 0.815; APRI AUROCs: 0.771, 0.754, and 0.749; all p < 0.001). FibroTouch required higher LSM thresholds than FibroScan at ≥ F2 (9.8 vs. 8.5 kPa) and ≥ F3 (13.1 vs 11.5 kPa). Cirrhosis ( β : −4.144, p = 0.001), Grade 4 hepatic inflammation ( β : −6.257, p = 0.001), and elevated alkaline phosphatase ( β : −0.004, p = 0.007) were independently associated with inter‐device discordance. Misclassification rates were 36.9% (125/339) for FibroTouch and 32.2% (109/339) for FibroScan, primarily due to overestimation. In the MAFLD subgroup ( n = 113), diagnostic accuracy remained high (AUROCs > 0.910), but threshold gaps widened further. Conclusion: FibroTouch and FibroScan provide comparable diagnostic accuracy for fibrosis staging in CLD. However, they are not interchangeable, and the use of device‐specific thresholds is mandatory to reduce misclassification, especially in patients with MAFLD.
- 4 May 2026
- Published by Wiley in Portal Hypertension & Cirrhosis
- Vol. 5 (2) , 129-139
Open AccessComparable Diagnostic Accuracy but Discordant Thresholds Between FibroTouch and FibroScan: A Biopsy‐Based Comparative Study
Aims: Accurate noninvasive fibrosis staging is essential in chronic liver disease (CLD). Although both FibroTouch and FibroScan are widely used, differences in technical design may affect measurement consistency. Whether their diagnostic thresholds for liver fibrosis are interchangeable remains unclear. The study aims to compare their diagnostic performance and threshold agreement in a biopsy‐confirmed CLD cohort. Methods: This single‐center, cross‐sectional study included 339 patients with biopsy‐confirmed CLD from February 2014 to March 2019, all of whom underwent biochemical testing, FibroTouch, and FibroScan. Diagnostic performance was evaluated using the area under the receiver operating characteristic curves (AUROCs). Univariable and multivariable linear models were used to identify factors associated with inter‐device liver stiffness measurement (LSM) differences. Misclassification was calculated using manufacturer‐recommended thresholds. Subgroup analysis was conducted among patients with metabolic dysfunction–associated fatty liver disease (MAFLD). Results: Both devices showed excellent diagnostic performance for detecting fibrosis ≥ F2, ≥ F3, and F4, with AUROCs exceeding 0.900, outperforming the fibrosis‐4 index (FIB‐4) and aspartate aminotransferase‐to‐platelet ratio index (APRI) in the entire cohort (FIB‐4 AUROCs: 0.775, 0.801, and 0.815; APRI AUROCs: 0.771, 0.754, and 0.749; all p < 0.001). FibroTouch required higher LSM thresholds than FibroScan at ≥ F2 (9.8 vs. 8.5 kPa) and ≥ F3 (13.1 vs 11.5 kPa). Cirrhosis ( β : −4.144, p = 0.001), Grade 4 hepatic inflammation ( β : −6.257, p = 0.001), and elevated alkaline phosphatase ( β : −0.004, p = 0.007) were independently associated with inter‐device discordance. Misclassification rates were 36.9% (125/339) for FibroTouch and 32.2% (109/339) for FibroScan, primarily due to overestimation. In the MAFLD subgroup ( n = 113), diagnostic accuracy remained high (AUROCs > 0.910), but threshold gaps widened further. Conclusion: FibroTouch and FibroScan provide comparable diagnostic accuracy for fibrosis staging in CLD. However, they are not interchangeable, and the use of device‐specific thresholds is mandatory to reduce misclassification, especially in patients with MAFLD.
- 1 January 2026
- Published by American Association for the Advancement of Science (AAAS) in Cyborg and Bionic Systems
- Vol. 7
Deep Learning to Identify Cognitive Impairment Across the Full Spectrum of Chronic Kidney Disease: Stage- and Cognition-Informed Feature Selection with a Dual-Branch Feature-Gated Network
Introduction: Cognitive impairment (CI) is a frequent and clinically relevant complication of chronic kidney disease (CKD), yet the neuroimaging features associated with CI remain incompletely characterized. This study developed a stage- and cognition-informed neuroimaging feature-selection framework and integrated the selected features into a Dual-Branch Feature-Gated Network (DBFG-Net) for identifying CKD with CI (CKD-CI). Methods: We enrolled a discovery cohort of 342 patients with CKD, including 177 with CI and 165 without CI, and 58 age- and sex-matched healthy controls. Multimodal magnetic resonance imaging features were extracted from T1-weighted imaging, arterial spin labeling, and quantitative susceptibility mapping. Stage-related imaging patterns were first characterized across CKD stages 1 to 5, followed by cognition-related comparisons between CKD-CI and CKD without CI. Features showing both stage-related linear trends and cognition-related discrimination were selected for DBFG-Net training and tested in temporal and multicenter external validation cohorts. Results: Structural morphology and tissue susceptibility showed significant stage-related linear trends across CKD stages, whereas cerebral blood flow showed no significant stage-related linear trend. Consistently, discriminative features for CKD-CI were confined to structural and susceptibility measures. DBFG-Net achieved area-under-the-receiver-operating-characteristic-curve values of 0.942 in the discovery cohort and 0.902 and 0.926 in the 2 external validation cohorts. Conclusion: The stage- and cognition-informed framework identified structural and susceptibility features relevant to CKD-CI. DBFG-Net demonstrated robust performance for CKD-CI identification across the discovery and external validation cohorts.
- 1 January 2026
- Published by American Association for the Advancement of Science (AAAS) in Cyborg and Bionic Systems
- Vol. 7
Deep Learning to Identify Cognitive Impairment Across the Full Spectrum of Chronic Kidney Disease: Stage- and Cognition-Informed Feature Selection with a Dual-Branch Feature-Gated Network
Introduction: Cognitive impairment (CI) is a frequent and clinically relevant complication of chronic kidney disease (CKD), yet the neuroimaging features associated with CI remain incompletely characterized. This study developed a stage- and cognition-informed neuroimaging feature-selection framework and integrated the selected features into a Dual-Branch Feature-Gated Network (DBFG-Net) for identifying CKD with CI (CKD-CI). Methods: We enrolled a discovery cohort of 342 patients with CKD, including 177 with CI and 165 without CI, and 58 age- and sex-matched healthy controls. Multimodal magnetic resonance imaging features were extracted from T1-weighted imaging, arterial spin labeling, and quantitative susceptibility mapping. Stage-related imaging patterns were first characterized across CKD stages 1 to 5, followed by cognition-related comparisons between CKD-CI and CKD without CI. Features showing both stage-related linear trends and cognition-related discrimination were selected for DBFG-Net training and tested in temporal and multicenter external validation cohorts. Results: Structural morphology and tissue susceptibility showed significant stage-related linear trends across CKD stages, whereas cerebral blood flow showed no significant stage-related linear trend. Consistently, discriminative features for CKD-CI were confined to structural and susceptibility measures. DBFG-Net achieved area-under-the-receiver-operating-characteristic-curve values of 0.942 in the discovery cohort and 0.902 and 0.926 in the 2 external validation cohorts. Conclusion: The stage- and cognition-informed framework identified structural and susceptibility features relevant to CKD-CI. DBFG-Net demonstrated robust performance for CKD-CI identification across the discovery and external validation cohorts.
- 9 November 2025
- Published by Wiley in Histopathology
- Vol. 88 (3) , 636-647
The validation of histological criteria from the IAIH‐PG to distinguish AIH from drug‐induced liver injury
Background and aims: To validate the applicability of the new histological criteria for autoimmune hepatitis (AIH) proposed by the International AIH Pathology Group (IAIH‐PG) among Chinese patients with AIH and drug‐induced liver injury (DILI). Methods: The gold standard for diagnosis relied on clinical response: discontinuing treatment without relapse supported DILI, while relapse or ongoing immunosuppressive treatment confirmed AIH. This two‐centre retrospective cohort study included inpatients with DILI or AIH from January 2002 to March 2023. Cases that underwent liver biopsy were selected according to inclusion and exclusion criteria. The diagnostic performance of the criteria was assessed by an area under the receiver operating characteristic curve (AUROC). Results: Out of 69 patients: AIH (41, 59%) and DILI (28, 41%). The accuracy, sensitivity and specificity of the new histological criteria for likely and possible AIH were 70%, 98% and 29%, respectively, with an AUROC of 0.8236 [95% confidence interval (CI): 0.7533–0.8938]. For likely AIH, the accuracy, sensitivity and specificity were 73%, 61% and 89%, respectively, with an AUROC of 0.9177 [95% CI: 0.8757–0.9596]. Moreover, for possible AIH, significant differences were found in serum alanine aminotransferase levels [178.4 (87.0, 435.0) versus 536.5 (206.9, 930.4) U/L] and antinuclear antibody (ANA) ≥1:160 [10 (67%) versus 1 (6%)], as well as in lobular lymphoplasmacytic infiltrate [15 (100%) versus 12 (71%)] and more than mild inflammation [13 (87%)versus 6 (35%)] between AIH and DILI (all P values were <0.05). Conclusion: The new histological criteria exhibit good diagnostic efficacy in distinguishing AIH from DILI in China, with high AUROC. Key discriminators include low aminotransferase, ANA ≥1:160, lobular lymphoplasmacytic infiltrate and more than mild inflammation, which may further improve diagnostic accuracy for AIH.
- 9 November 2025
- Published by Wiley in Histopathology
- Vol. 88 (3) , 636-647
The validation of histological criteria from the IAIH‐PG to distinguish AIH from drug‐induced liver injury
Background and aims: To validate the applicability of the new histological criteria for autoimmune hepatitis (AIH) proposed by the International AIH Pathology Group (IAIH‐PG) among Chinese patients with AIH and drug‐induced liver injury (DILI). Methods: The gold standard for diagnosis relied on clinical response: discontinuing treatment without relapse supported DILI, while relapse or ongoing immunosuppressive treatment confirmed AIH. This two‐centre retrospective cohort study included inpatients with DILI or AIH from January 2002 to March 2023. Cases that underwent liver biopsy were selected according to inclusion and exclusion criteria. The diagnostic performance of the criteria was assessed by an area under the receiver operating characteristic curve (AUROC). Results: Out of 69 patients: AIH (41, 59%) and DILI (28, 41%). The accuracy, sensitivity and specificity of the new histological criteria for likely and possible AIH were 70%, 98% and 29%, respectively, with an AUROC of 0.8236 [95% confidence interval (CI): 0.7533–0.8938]. For likely AIH, the accuracy, sensitivity and specificity were 73%, 61% and 89%, respectively, with an AUROC of 0.9177 [95% CI: 0.8757–0.9596]. Moreover, for possible AIH, significant differences were found in serum alanine aminotransferase levels [178.4 (87.0, 435.0) versus 536.5 (206.9, 930.4) U/L] and antinuclear antibody (ANA) ≥1:160 [10 (67%) versus 1 (6%)], as well as in lobular lymphoplasmacytic infiltrate [15 (100%) versus 12 (71%)] and more than mild inflammation [13 (87%)versus 6 (35%)] between AIH and DILI (all P values were <0.05). Conclusion: The new histological criteria exhibit good diagnostic efficacy in distinguishing AIH from DILI in China, with high AUROC. Key discriminators include low aminotransferase, ANA ≥1:160, lobular lymphoplasmacytic infiltrate and more than mild inflammation, which may further improve diagnostic accuracy for AIH.
- Open Access
- 30 April 2025
- Published by Elsevier in Annals of Hepatology
- Vol. 30 (2) , 101921
Impact of hepatitis B surface antigen quantification on achieving a functional cure in patients with chronic hepatitis B: A systematic review and meta-analysis
- 30 April 2025
- Published by Elsevier in Annals of Hepatology
- Vol. 30 (2) , 101921
Open AccessImpact of hepatitis B surface antigen quantification on achieving a functional cure in patients with chronic hepatitis B: A systematic review and meta-analysis
- Open Access
- 10 March 2025
- Published by Wiley in Health Science Reports
- Vol. 8 (3)
The Effect of Nonalcoholic Fatty Liver Disease on Extrahepatic Cancers: Evidence From Population‐Based Cohort and Mendelian Randomization
Background and Aims: Nonalcoholic fatty liver disease (NAFLD) is an escalating global health concern with significant implications for cancers. A better understanding of the causal relationship between NAFLD and extrahepatic cancers might help in clinical management of NAFLD and prevent its adverse outcomes.Methods: This study encompassed two complementary approaches. First, the cross‐sectional analysis was performed to examine the association between NAFLD and extrahepatic cancers, utilizing individual‐level data from the National Health and Nutrition Examination Survey (2017‐March 2020, 2021‐2023 cycles). Logistic regression model was utilized to evaluate the association. Subsequently, Mendelian randomization (MR) analysis was conducted to explore the causal association between NAFLD and extrahepatic cancers. Summary‐level data for genetically predicted NAFLD and extrahepatic cancers were derived from large‐scale genome‐wide association studies (GWAS), IEU Open GWAS project and the UK Biobank. The inverse variance weighting (IVW) method with a random‐effect model was utilized as the main analysis.Results: A total of 10,010 participants were included in the cross‐sectional analysis. No association was observed between NAFLD and extrahepatic cancers after adjusting for potential confounders, with odd ratios (ORs) ranging from 0.872 to 2.171. IVW MR analysis showed genetic liability to genetically predicted cALT and imaging‐and‐biopsy confirmed NAFLD were not causally associated with extrahepatic cancers, with ORs ranging from 0.957 to 1.118 (all p > 0.050). Moreover, genetically predicted cALT and imaging‐and‐biopsy confirmed NAFLD were causally associated with liver & bile duct cancer (OR = 1.001, 95% CI = 1.000–1.001, p = 0.011; OR = 1.001, 95% CI = 1.000–1.001, p < 0.001), reinforcing a well‐documented link between NAFLD and liver & bile duct cancer.Conclusion: Our findings demonstrated that NAFLD was not causally associated with common extrahepatic cancers. Further research is required to validate these results from a mechanistic perspective.
- 10 March 2025
- Published by Wiley in Health Science Reports
- Vol. 8 (3)
Open AccessThe Effect of Nonalcoholic Fatty Liver Disease on Extrahepatic Cancers: Evidence From Population‐Based Cohort and Mendelian Randomization
Background and Aims: Nonalcoholic fatty liver disease (NAFLD) is an escalating global health concern with significant implications for cancers. A better understanding of the causal relationship between NAFLD and extrahepatic cancers might help in clinical management of NAFLD and prevent its adverse outcomes.Methods: This study encompassed two complementary approaches. First, the cross‐sectional analysis was performed to examine the association between NAFLD and extrahepatic cancers, utilizing individual‐level data from the National Health and Nutrition Examination Survey (2017‐March 2020, 2021‐2023 cycles). Logistic regression model was utilized to evaluate the association. Subsequently, Mendelian randomization (MR) analysis was conducted to explore the causal association between NAFLD and extrahepatic cancers. Summary‐level data for genetically predicted NAFLD and extrahepatic cancers were derived from large‐scale genome‐wide association studies (GWAS), IEU Open GWAS project and the UK Biobank. The inverse variance weighting (IVW) method with a random‐effect model was utilized as the main analysis.Results: A total of 10,010 participants were included in the cross‐sectional analysis. No association was observed between NAFLD and extrahepatic cancers after adjusting for potential confounders, with odd ratios (ORs) ranging from 0.872 to 2.171. IVW MR analysis showed genetic liability to genetically predicted cALT and imaging‐and‐biopsy confirmed NAFLD were not causally associated with extrahepatic cancers, with ORs ranging from 0.957 to 1.118 (all p > 0.050). Moreover, genetically predicted cALT and imaging‐and‐biopsy confirmed NAFLD were causally associated with liver & bile duct cancer (OR = 1.001, 95% CI = 1.000–1.001, p = 0.011; OR = 1.001, 95% CI = 1.000–1.001, p < 0.001), reinforcing a well‐documented link between NAFLD and liver & bile duct cancer.Conclusion: Our findings demonstrated that NAFLD was not causally associated with common extrahepatic cancers. Further research is required to validate these results from a mechanistic perspective.
- Open Access
- 5 December 2024
- Published by Wiley in CNS Neuroscience & Therapeutics
- Vol. 30 (12) , e70151
Combination of rs‐fMRI, QSM, and ASL Reveals the Cerebral Neurovascular Coupling Dysfunction Is Associated With Cognitive Decline in Patients With Chronic Kidney Disease
Background: Neurovascular coupling (NVC) reflects the close connection between neural activity and cerebral blood flow (CBF) responses, providing new insights to explore the neuropathological mechanisms of various diseases. Non‐dialysis patients with chronic kidney disease (CKD) exhibit cognitive decline, but the underlying pathological mechanisms are unclear.Methods: The prospective study involved 53 patients with stage 1–3a CKD (CKD1–3a), 78 patients with stage 3b–5 CKD (CKD3b–5), and 52 healthy controls (HC). Our investigation involved voxel‐based assessments of both global and regional BOLD signal characteristics. Additionally, we explored the correlations between neuroimaging indices, Montreal Cognitive Assessment (MoCA) scores, and clinical laboratory findings.Results: Compared to HC, the CKD3b–5 and CKD1–3a groups exhibited lower ALLF and ReHo in the default mode network (DMN), higher CBF in bilateral hippocampus (HIP), higher susceptibility values in bilateral caudate nucleus (CAU) and putamen (PUT), and lower susceptibility values in bilateral HIP. At the global level, the coupling coefficients were lower in CKD1–3a and CKD3b–5 groups than in HC. At the ROI level, the CBF‐ALFF and CBF‐ReHo coupling in HIP and basal ganglia regions were lower in CKD3b–5 groups than in the CKD1–3a group. Most importantly, susceptibility‐ALFF in ANG.R may mediate the effects of phosphorus on cognitive decompensation in patients with CKD1‐3a.Conclusions: Non‐dialysis patients with CKD exhibit abnormal NCV, which is associated with the cognitive decline. Specifically, the susceptibility‐ALFF may serve as a valuable biomarker for early assessment of cognitive decline in CKD, offering insights into the pathogenesis of cognitive decline in CKD.
- 5 December 2024
- Published by Wiley in CNS Neuroscience & Therapeutics
- Vol. 30 (12) , e70151
Open AccessCombination of rs‐fMRI, QSM, and ASL Reveals the Cerebral Neurovascular Coupling Dysfunction Is Associated With Cognitive Decline in Patients With Chronic Kidney Disease
Background: Neurovascular coupling (NVC) reflects the close connection between neural activity and cerebral blood flow (CBF) responses, providing new insights to explore the neuropathological mechanisms of various diseases. Non‐dialysis patients with chronic kidney disease (CKD) exhibit cognitive decline, but the underlying pathological mechanisms are unclear.Methods: The prospective study involved 53 patients with stage 1–3a CKD (CKD1–3a), 78 patients with stage 3b–5 CKD (CKD3b–5), and 52 healthy controls (HC). Our investigation involved voxel‐based assessments of both global and regional BOLD signal characteristics. Additionally, we explored the correlations between neuroimaging indices, Montreal Cognitive Assessment (MoCA) scores, and clinical laboratory findings.Results: Compared to HC, the CKD3b–5 and CKD1–3a groups exhibited lower ALLF and ReHo in the default mode network (DMN), higher CBF in bilateral hippocampus (HIP), higher susceptibility values in bilateral caudate nucleus (CAU) and putamen (PUT), and lower susceptibility values in bilateral HIP. At the global level, the coupling coefficients were lower in CKD1–3a and CKD3b–5 groups than in HC. At the ROI level, the CBF‐ALFF and CBF‐ReHo coupling in HIP and basal ganglia regions were lower in CKD3b–5 groups than in the CKD1–3a group. Most importantly, susceptibility‐ALFF in ANG.R may mediate the effects of phosphorus on cognitive decompensation in patients with CKD1‐3a.Conclusions: Non‐dialysis patients with CKD exhibit abnormal NCV, which is associated with the cognitive decline. Specifically, the susceptibility‐ALFF may serve as a valuable biomarker for early assessment of cognitive decline in CKD, offering insights into the pathogenesis of cognitive decline in CKD.
- 23 November 2024
- Published by Elsevier in Digestive and Liver Disease
- Vol. 57 (3) , 730-737
Porto-sinusoidal vascular disorder with known etiologies had more severe portal hypertension and poorer outcomes
- 23 November 2024
- Published by Elsevier in Digestive and Liver Disease
- Vol. 57 (3) , 730-737
Porto-sinusoidal vascular disorder with known etiologies had more severe portal hypertension and poorer outcomes
- Open Access
- 11 March 2024
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 8 (4)
Validation of the revised electronic version of RUCAM for diagnosis of DILI in Chinese patients
Background & Aims: The Revised Electronic Causality Assessment Method (RECAM), a computerized update of the Roussel Uclaf Causality Assessment Methodology (RUCAM), was recently proposed. In this study, we validated and compared the utility of the RECAM and RUCAM in Chinese patients with a single conventional or herbal agent-induced liver injury. Methods: In this retrospective multicenter cohort of well-established DILI and non-DILI patients from 5 centers in China, the diagnostic performance of the RUCAM and RECAM was compared by AUC analysis. The consistency was evaluated by weighted kappa. The major causes of discrepancy were explored. Results: A total of 481 DILI and 100 non-DILI patients were included. In total, 62.6% of the DILI cases were induced by conventional agents, and 37.4% were induced by herbs. The RECAM had relatively higher AUC than RUCAM for overall [0.947 (0.926–0.964) vs. 0.867 (0.836–0.893), p=0.0016], conventional agents [0.923 (0.890–0.949) vs. 0.819 (0.775–0.858), p=0.0185], and herbs [0.972 (0.941–0.989) vs.0.911 (0.866–0.944), p=0.0199]. Latency, scores associated with hepatitis B, and hepatotoxicity information of the insulting drugs were the 3 main causes for the inconsistency between RECAM and RUCAM scores. Conclusions: The RECAM had relatively better diagnostic performance than RUCAM, with a higher AUC for Chinese DILI patients. Timely updates of the LiverTox category and refinement of serum markers to exclude hepatitis B activity would further improve the applicability of RECAM in areas where the use of herbs and resolution of past HBV infections are common.
- 11 March 2024
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 8 (4)
Open AccessValidation of the revised electronic version of RUCAM for diagnosis of DILI in Chinese patients
Background & Aims: The Revised Electronic Causality Assessment Method (RECAM), a computerized update of the Roussel Uclaf Causality Assessment Methodology (RUCAM), was recently proposed. In this study, we validated and compared the utility of the RECAM and RUCAM in Chinese patients with a single conventional or herbal agent-induced liver injury. Methods: In this retrospective multicenter cohort of well-established DILI and non-DILI patients from 5 centers in China, the diagnostic performance of the RUCAM and RECAM was compared by AUC analysis. The consistency was evaluated by weighted kappa. The major causes of discrepancy were explored. Results: A total of 481 DILI and 100 non-DILI patients were included. In total, 62.6% of the DILI cases were induced by conventional agents, and 37.4% were induced by herbs. The RECAM had relatively higher AUC than RUCAM for overall [0.947 (0.926–0.964) vs. 0.867 (0.836–0.893), p=0.0016], conventional agents [0.923 (0.890–0.949) vs. 0.819 (0.775–0.858), p=0.0185], and herbs [0.972 (0.941–0.989) vs.0.911 (0.866–0.944), p=0.0199]. Latency, scores associated with hepatitis B, and hepatotoxicity information of the insulting drugs were the 3 main causes for the inconsistency between RECAM and RUCAM scores. Conclusions: The RECAM had relatively better diagnostic performance than RUCAM, with a higher AUC for Chinese DILI patients. Timely updates of the LiverTox category and refinement of serum markers to exclude hepatitis B activity would further improve the applicability of RECAM in areas where the use of herbs and resolution of past HBV infections are common.